<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>NEWSTRON &#187; M&amp;A</title>
	<atom:link href="http://newstron.com/category/ma/feed/" rel="self" type="application/rss+xml" />
	<link>http://newstron.com</link>
	<description>Global News &#38; Press Releases</description>
	<lastBuildDate>Tue, 21 Feb 2012 18:25:48 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Forma Therapeutics Announces $200 mn Collaboration Deal with Novartis</title>
		<link>http://newstron.com/forma-therapeutics-announces-200-mn-collaboration-deal-with-novartis/</link>
		<comments>http://newstron.com/forma-therapeutics-announces-200-mn-collaboration-deal-with-novartis/#comments</comments>
		<pubDate>Tue, 13 Jan 2009 10:55:18 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Americas]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Capital Markets]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[JVs]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Basel]]></category>
		<category><![CDATA[Broad Institute]]></category>
		<category><![CDATA[Collaboration]]></category>
		<category><![CDATA[Drug Discovery Platform]]></category>
		<category><![CDATA[Forma Therapeutics]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[Harvard]]></category>
		<category><![CDATA[Michael Foley]]></category>
		<category><![CDATA[MIT]]></category>
		<category><![CDATA[Novartis Option Fund]]></category>
		<category><![CDATA[Novartis Venture Funds]]></category>
		<category><![CDATA[Protein-protein interactions]]></category>
		<category><![CDATA[Reinhard Ambros]]></category>
		<category><![CDATA[Steven Tregay]]></category>
		<category><![CDATA[Stuart Schreiber]]></category>
		<category><![CDATA[Switzerland]]></category>
		<category><![CDATA[Todd Golub]]></category>
		<category><![CDATA[transformative biology]]></category>

		<guid isPermaLink="false">http://newstron.com/forma-therapeutics-announces-200-mn-collaboration-deal-with-novartis/</guid>
		<description><![CDATA[CAMBRIDGE, Mass. Jan 12, 2009 &#8212; FORMA Therapeutics announced today that it has entered into a license and option agreement through the Novartis Option Fund. Under the terms of the agreement, FORMA will leverage its transformative biology and chemistry platform to develop inhibitors for an undisclosed protein-protein interaction target in the field of oncology. The [...]]]></description>
		<wfw:commentRss>http://newstron.com/forma-therapeutics-announces-200-mn-collaboration-deal-with-novartis/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>IBM to Acquire ILOG</title>
		<link>http://newstron.com/ibm-to-acquire-ilog/</link>
		<comments>http://newstron.com/ibm-to-acquire-ilog/#comments</comments>
		<pubDate>Mon, 28 Jul 2008 16:13:37 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Americas]]></category>
		<category><![CDATA[Computing]]></category>
		<category><![CDATA[Data Management]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[Software]]></category>
		<category><![CDATA[Technology]]></category>

		<guid isPermaLink="false">http://newstron.com/ibm-to-acquire-ilog/</guid>
		<description><![CDATA[ 					 					ARMONK, NY	 					 					 					 					 &#38; PARIS		 					 					 					 									 					 					 					 									 									 					-	 					  					28 Jul 2008: 					 				 					IBM (NYSE: IBM) and ILOG (NASDAQ: ILOG; Euronext: ILO, ISIN: FR0004042364) today announced they have signed an agreement regarding a proposed acquisition by IBM of ILOG to be [...]]]></description>
		<wfw:commentRss>http://newstron.com/ibm-to-acquire-ilog/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Glu Mobile offers $36 million to acquire Superscape</title>
		<link>http://newstron.com/glu-mobile-offers-36-million-to-acquire-superscape/</link>
		<comments>http://newstron.com/glu-mobile-offers-36-million-to-acquire-superscape/#comments</comments>
		<pubDate>Wed, 23 Jan 2008 12:13:19 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[M&A]]></category>
		<category><![CDATA[Mobile]]></category>
		<category><![CDATA[New Media]]></category>
		<category><![CDATA[Telecom]]></category>

		<guid isPermaLink="false">http://newstron.com/glu-mobile-offers-36-million-to-acquire-superscape/</guid>
		<description><![CDATA[SAN MATEO, Calif.&#8211;(BUSINESS WIRE)&#8211;Glu Mobile Inc. (“Glu”) (NASDAQ:GLUU &#8211; News) today announced a tender offer to acquire Superscape Group plc (“Superscape”) (LSE:SPS &#8211; News), a leading developer and publisher of mobile games. The acquisition of Superscape will considerably expand Glu’s US presence and add significant development and publishing capabilities to Glu’s existing world-class resources.
The offer [...]]]></description>
		<wfw:commentRss>http://newstron.com/glu-mobile-offers-36-million-to-acquire-superscape/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Questex Media Acquires FierceMarkets</title>
		<link>http://newstron.com/questex-media-acquires-fiercemarkets/</link>
		<comments>http://newstron.com/questex-media-acquires-fiercemarkets/#comments</comments>
		<pubDate>Tue, 22 Jan 2008 22:07:15 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Advertising]]></category>
		<category><![CDATA[Americas]]></category>
		<category><![CDATA[Asia-Pacific]]></category>
		<category><![CDATA[Communications]]></category>
		<category><![CDATA[Data Management]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[Marketing]]></category>
		<category><![CDATA[New Media]]></category>
		<category><![CDATA[Publishing]]></category>

		<guid isPermaLink="false">http://newstron.com/questex-media-acquires-fiercemarkets/</guid>
		<description><![CDATA[New York, NY January 22, 2008 &#8211; FierceMarkets (www.fiercemarkets.com), a leading online B2B media company, has announced its acquisition by Questex Media Group, Inc. (www.questex.com), a global, diversified business-to-business integrated media and information provider headquartered in Newton, MA.
The Jordan, Edmiston Group, Inc. (www.jegi.com), a New York-based independent investment bank that specializes in media and information, [...]]]></description>
		<wfw:commentRss>http://newstron.com/questex-media-acquires-fiercemarkets/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biogen Idec completes Review of Strategic Alternatives</title>
		<link>http://newstron.com/biogen-idec-completes-review-of-strategic-alternatives/</link>
		<comments>http://newstron.com/biogen-idec-completes-review-of-strategic-alternatives/#comments</comments>
		<pubDate>Thu, 13 Dec 2007 19:41:09 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[Pharma]]></category>

		<guid isPermaLink="false">http://newstron.com/biogen-idec-completes-review-of-strategic-alternatives/</guid>
		<description><![CDATA[ BIOGEN IDEC COMPLETES REVIEW OF STRATEGIC ALTERNATIVES
Company to Remain Independent
Cambridge, MA, December 12, 2007 &#8211; The Board of Directors of Biogen today announced that, after completing a review of strategic alternatives to maximize shareholder value, Biogen Idec will continue on its present course as an independent Company.
On October 12, the Board announced the start [...]]]></description>
		<wfw:commentRss>http://newstron.com/biogen-idec-completes-review-of-strategic-alternatives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

